Browse Category: Medical > Disease: Central Nervous System

Categories

[Search within category]

Retractable Step Cannula For Brain Delivery Of Therapeutics

An adjustable step cannula to minimize therapeutic agent leakage and maximize on-target drug delivery. This new cannula design improves brain drug delivery over current fixed-length step cannulas.

A Novel Method to Generate Specific and Permanent Macromolecular Covalent Inhibitors

UCSF researchers have invented a novel method to generate covalent macromolecular inhibitors. This strategy allows a peptide inhibitor to bind to its target protein specifically and irreversibly through proximity-enabled bioreactivity.

Omnidirectional MRI Catheter Resonator for Interventional Procedures

This invention describes an orientation-independent device that can create bright and highly localized signal enhancement during magnetic resonance imaging.

Cell Aging Measured by Telomere Length and Telomerase Activity as a Diagnostic and Prognostic Biomarker of Major Depressive Disorder

This invention describes a new way to predict response to antidepressants in patients with Major Depressive Disorder (MDD) and the likelihood of developing the disease by measuring telomere length and telomerase activity.

Closed-Loop Stimulation Device for Enhancing Motor Function After Stroke

This novel brain stimulation device enhances motor function after stroke by modulating the neural network to be more excitable in a task-dependent manner.

Method And System For Diagnosing And Training Cognitive Fitness And Targeted Neural Network Function Underlying Cognitive Fitness In An Integrated...

This invention is a novel video game that integrates cognitive and neural training in real-time to improve cognitive function.

Novel Software for Generating Attenuation Correction Maps with MRI for PET Reconstruction

This invention can accurately and rapidly map patient bone structure and classify all tissue types such as fatty soft tissue, water soft tissue, lung tissue, bone, and air within a single scan using novel MRI acquisition and reconstruction techniques.

A Novel Method of Removing Stimulation Artifacts (SA) from Multichannel Electrical Recordings

This technology is a novel algorithm that can significantly remove stimulation artifacts (SA) from electrophysiological recording devices used for neuroscience research and/or clinical therapeutics.

A Blood-based Diagnostic Test for Early Stage Detection of Autism Spectrum Disorders (ASD)

A revolutionary blood-based diagnostic test measures three kinase signaling pathway activities to determine the likelihood of the patient having ASD at an early stage.

USE OF NEURONAL PRECURSOR CELLS TO TREAT DISEASES AND DISORDERS OF THE BRAIN

This invention identifies a novel pool of interneuron precursors that can be used for regenerative approaches in the central nervous system.

Age- and Disease-related Cognitive Dysfunction Treatment

This invention includes methods and compositions for treating and preventing cognitive problems across the lifespan, including in aging and disease.

An Automated, Minimally-invasive Neural Interface System Providing the Means for Scalable Electrode Implantation

This invention provides an automated, high-throughput, minimally-invasive system to insert electrodes within the brain and other parts of the central nervous system (CNS). The system provides a means for inserting these electrodes within the brain with minimal to no disruption of the blood brain barrier (BBB). This feature is critical, as neural electrode failure is closely associated with inflammation resulting from the disruption of the BBB. Furthermore, this system will allow the implantation of electrodes within the CNS at a much higher density than current standards.

HIGH-THROUGHPUT SYSTEM TO MEASURE INTRACELLULAR POLYGLUTAMINE PROTEIN AGGREGATION USING FLUORESCENCE RESONANCE ENERGY TRANSFER

This invention identifies a novel high-throughput assay to quantify intracellular polyglutamine protein aggregates and identify potential therapeutic targets involved in the regulation of protein aggregation. 

Modular Cell and Drug Delivery Cannula System

The use of cell transplantation in the brain shows great promise for the treatment of human neurological diseases, such as Parkinson's disease or stroke. Indeed, pre-clinical studies in animal models have shown significantly improved neurological function following cell grafting. However, in human trials the results have been considerably more variable. This has, in part, been attributed to concerns with poor cell distribution within the target area. A further issue that has arisen with the challenge of scaling up from animal models to humans is the increase in the number of transcortical penetrations required to deliver therapeutic agents. For surgical cell transplantation approaches, cell sedimentation and impaired graft viability are also concerns that need to be addressed to optimize the use of this therapeutic avenue.

Treatment for a Central Nervous System Disease - NMO

Neuromyelitis optica (NMO) is a disease syndrome of the central nervous system (CNS) that primarily affects the spinal cord and optic nerve, producsing paralysis and blindness.  Reports indicate that there are 4,000 cases of NMO in the United States and a half million worldwide.  This demyelinating disease is caused by the blinding of pathogenic autoantibodies (NMO-IgG) to aquaporin-4 (AQP4), a plasma membrane water transporting protein expressed on astrocytes throughout the CNS.  The blinding initiates complement-dependent cytotoxicity (CDC), resulting in inflammation, local disruption of the blood-brain barrier, and damage to oligodendrocytes and neurons.  Current NMO therapies have limited efficacy and potential long-term side effects.  Hence, there is a need for a novel approach to treat NMO.

Novel, less invasive biomarker to detect and monitor Parkinson's disease and other movement disorders

Parkinson’s disease (PD) and primary dystonia  are common brain disorders that affect movement. Performing daily activities becomes increasing difficult and medication is insufficient for treatment of symptoms as severity increases. The best current technology for treatment of these disorders is deep brain stimulation (DBS) which uses stimulator electrodes inserted in the basal ganglia to alter electrical signaling. Determination of optimal stimulation is based on a “trial & error” approach and there is no accurate way to guide the therapy.  Stimulation is performed as an “open loop”, meaning that there is no brain signal that can be used to monitor the effectiveness of therapy and control the stimulation automatically. Hence, programming of the stimulation requires several time consuming appointments before the optimal setting is determined; thus making it difficult to achieve immediate symptom relief. Identification of a novel method to guide DBS therapy for PD and dystonia is greatly needed.

Small Molecule Inhibitors of IRE1 for Unfolded Protein Response (UPR)-Dependent Diseases

Novel small molecules that effectively inhibit IRE1, an enzyme critical for the activation of the unfolded protein response (UPR), providing a new method for therapeutic intervention in UPR-dependent diseases, such as cancer, inflammatory disease, autoimmune disease, and neurodegeneration.

Novel, Real-Time Method for Brain Mapping

The ability to map important brain regions (e.g. sensory and motor cortex) is critical for surgical procedures that require precise information of neural activity so that neurosurgeons can safely operate. The current state of the art relies on electrical cortical stimulation that is not only inefficient but also relies on electric shock thereby generating non-physiologic activity from the areas sampled, and such stimulation can also cause dangerous seizures. Furthermore, electrical stimulation mapping frequently misrepresents and underestimates the extent of the functional cortex, leading to neurologic impairments in patients despite comprehensive mapping. Additionally, inaccurate mapping by electrical stimulation may also lead to incomplete resection of a tumor or epilepsy focus to preserve the tissue whose function is not clearly identified or incomplete, resulting in tumor regrowth or continued intractable seizures, respectively.   What neurologists and neurosurgeons need is a safe and efficient functional brain mapping tool that will allow them to accurately perform cortical tissue resections without compromising critical brain regions.

A safe and reliable device for endovascular biopsy

UCSF inventors have developed a safe endovascular biopsy device for extraction of endothelial cells from the blood vessel wall.

RECOMBINANT HUMAN PROTEIN THAT PROMOTES NEURITE GROWTH IN VITRO

UCSF researchers have produced a recombinant chimeric human protein that promotes neurite growth in vitro and that can be used as an alternative to the widely used cell adhesion molecule laminin, for cell attachment, neurite outgrowth studies, as well as other cell biology and immunology applications.

Novel Therapy for Treatment of Chronic Degenerative Brain Diseases

There are many types of neurological diseases that affect infants and children. Although the frequency of individual disorders is not high, together they are a significant group of disorders with a collective frequency of 1 in 18,000 live births. Unfortunately, neurologic disease is seldom curable. Thus, strategies for the treatment of these debilitating and often fatal diseases frequently focus primarily on palliative measures. Attempts at curing neurological disease have also been proposed. These treatments have included enzyme replacement therapy, gene therapy, and allogenic bone marrow transplantation. Sadly, however, these treatments typically do not improve the condition nor alter the ultimate outcome of the disease, leaving a desperate need to develop effective therapies.

TREATMENT OF ALZHEIMERS DISEASE

A UCSF investigator has identified a potential target for the treatment, and possible prevention, of Alzheimers Disease. Due to the nature of this target, inhibitors developed against this target should cause fewer side effects than current pharmaceuticals used to treat AD. Unlike current palliative treatments, such inhibitors would potentially be the first treatments with disease-modifying properties and the ability to stop disease progression.

  • Go to Page:

ADDRESS

UCSF
Office of Innovation, Technology & Alliances

3333 California Street, Suite S-11,
San Francisco,CA 94143-1209